Seven Eight Capital, LP Supernus Pharmaceuticals, Inc. Transaction History

Seven Eight Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 12, 2019	SELL	$29.96 - $38.87 $1.19 Million - $1.54 Million	-39,655 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $1.3 Million - $1.67 Million	39,655 New	39,655 $1.39 Million
Q4 2018 Feb 14, 2019	SELL	$30.84 - $49.51 $451,960 - $725,569	-14,655 Closed	0 $0
Q3 2018 Oct 18, 2018	BUY	$42.7 - $56.55 $625,768 - $828,740	14,655 New	14,655 $738,000
Q3 2017 Oct 16, 2017	SELL	$36.75 - $49.65 $11,025 - $14,895	-300 Closed	0 $0
Q2 2017 Aug 10, 2017	BUY	N/A	300	300 $13,000

282

60.9M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.